These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34278933)

  • 21. Resistance Mechanisms to Targeted Therapies in
    McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
    Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
    [No Abstract]   [Full Text] [Related]  

  • 22. Tumour heterogeneity and resistance to cancer therapies.
    Dagogo-Jack I; Shaw AT
    Nat Rev Clin Oncol; 2018 Feb; 15(2):81-94. PubMed ID: 29115304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
    Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
    Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lung Cancer Heterogeneity and New Strategies for Drug Therapy.
    Wang DC; Wang W; Zhu B; Wang X
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():531-546. PubMed ID: 28977762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer.
    Kruglyak KM; Lin E; Ong FS
    Adv Exp Med Biol; 2016; 890():123-36. PubMed ID: 26703802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy.
    Wu D; Wang DC; Cheng Y; Qian M; Zhang M; Shen Q; Wang X
    Semin Cancer Biol; 2017 Feb; 42():13-19. PubMed ID: 27840278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors.
    Spagnuolo A; Maione P; Gridelli C
    Expert Opin Emerg Drugs; 2018 Sep; 23(3):231-241. PubMed ID: 30251885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clonal Evolution of MEK/MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case.
    Lehtomaki KI; Lahtinen LI; Rintanen N; Kuopio T; Kholova I; Makela R; Rantala JK; Kellokumpu-Lehtinen PL; Kononen J
    Anticancer Res; 2019 Nov; 39(11):5867-5877. PubMed ID: 31704811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal growth factor receptor T790M testing in progressed lung cancer: A review of sensitive methods for analysis of tissue and liquid biopsy samples.
    Chougule A; Basak S
    Indian J Cancer; 2017 Dec; 54(Supplement):S45-S54. PubMed ID: 29292708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer.
    Murtuza A; Bulbul A; Shen JP; Keshavarzian P; Woodward BD; Lopez-Diaz FJ; Lippman SM; Husain H
    Cancer Res; 2019 Feb; 79(4):689-698. PubMed ID: 30718357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.
    Galvani E; Alfieri R; Giovannetti E; Cavazzoni A; La Monica S; Galetti M; Fumarola C; Bonelli M; Mor M; Tiseo M; Peters GJ; Petronini PG; Ardizzoni A
    Curr Pharm Des; 2013; 19(5):818-32. PubMed ID: 22973953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Harnessing Tumor Evolution to Circumvent Resistance.
    Pogrebniak KL; Curtis C
    Trends Genet; 2018 Aug; 34(8):639-651. PubMed ID: 29903534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.
    Hua G; Zhang X; Zhang M; Wang Q; Chen X; Yu R; Bao H; Liu J; Wu X; Shao Y; Liang B; Lu K
    ESMO Open; 2022 Feb; 7(1):100337. PubMed ID: 35123209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
    Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
    Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acquired Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples.
    Guerini-Rocco E; Passaro A; Casadio C; De Luca VM; Guarize J; de Marinis F; Vacirca D; Barberis M
    Arch Pathol Lab Med; 2018 Apr; 142(4):465-473. PubMed ID: 29565206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
    Recondo G; Bahcall M; Spurr LF; Che J; Ricciuti B; Leonardi GC; Lo YC; Li YY; Lamberti G; Nguyen T; Milan MSD; Venkatraman D; Umeton R; Paweletz CP; Albayrak A; Cherniack AD; Price KS; Fairclough SR; Nishino M; Sholl LM; Oxnard GR; Jänne PA; Awad MM
    Clin Cancer Res; 2020 Jun; 26(11):2615-2625. PubMed ID: 32034073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
    Dagogo-Jack I; Yoda S; Lennerz JK; Langenbucher A; Lin JJ; Rooney MM; Prutisto-Chang K; Oh A; Adams NA; Yeap BY; Chin E; Do A; Marble HD; Stevens SE; Digumarthy SR; Saxena A; Nagy RJ; Benes CH; Azzoli CG; Lawrence MS; Gainor JF; Shaw AT; Hata AN
    Clin Cancer Res; 2020 Jun; 26(11):2535-2545. PubMed ID: 32086345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.
    Mayo-de-Las-Casas C; Garzón Ibáñez M; Jordana-Ariza N; García-Peláez B; Balada-Bel A; Villatoro S; Malapelle U; Karachaliou N; Troncone G; Rosell R; Molina-Vila MA
    Expert Rev Mol Diagn; 2018 Jan; 18(1):35-45. PubMed ID: 29172773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.